ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Oct 6, 2015
Attention to Pricing Issues Pressures Valeant
Along with the biotech industry as a whole, Valeant Pharmaceuticals has been the subject of negative publicity lately, and its shares have paid the price.
Sep 28, 2015
Biotechs Bruised
If one is gambling on the drugs of the future, then one must also deal with the uncertainties of the present. Regulatory risk has taken the air out of the biotech space.
Sep 25, 2015
Janet Yellen, the Positive GDP Revision, and Nike’s Swoosh
Finally, there’s some good news, but nothing that could change the stormy overall picture.
Aug 20, 2015
The Flight to Safety
The wave of selling may have just begun.
Jul 23, 2015
Guide to Second Quarter Earnings; Big Pharma Experiencing Earnings Momentum
Abbott, Bristol-Myers, Celgene, Eli Lilly, Novartis, Roche, Valeant…
Dec 26, 2014
HCV Competition Not New “News” for Gilead
Gilead is trading more than 40% above its 52-week low and about 20% from its 52-week high. We see no reason to panic, and the company’s trading activity more closely reflects a company whose stock price has quintupled in recent years than one that is in any trouble whatsoever. Gilead’s shares bounced right off technical support levels, and we see a long term that is still very bright for the biotech. Gilead’s shares remain underpriced even under a bear-case scenario.
Can Vertex Pharmaceuticals Dominate the Race to Treat Cystic Fibrosis?
Cystic Fibrosis is a rare disease that afflicts an estimated seventy-five thousand patients worldwide. Vertex Pharmaceuticals is the first to market with a combination treatment to treat a portion of the overall patient population. Will Vertex win the race to bring forth a triple therapy to treat the vast majority of those afflicted?


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.